✦ LIBER ✦

Adjuvant chemotherapy in stage-II breast cancer: An overview of the NSABP clinical trials

✍ Scribed by Norman Wolmark; Bernard Fisher

Publisher: Springer US
Year: 1983
Tongue: English
Weight: 778 KB
Volume: 3
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf01855123

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant chemotherapy in stage II breast

Adjuvant chemotherapy in stage II breast cancer: A brief overview of the NSABP clinical trials

✍ Norman Wolmark; Bernard Fisher 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 691 KB

Adjuvant tamoxifen and chemotherapy in s

Adjuvant tamoxifen and chemotherapy in stage II breast cancer: Interim findings from NSABP protocol B-09

✍ Norman Wolmark; Bernard Fisher 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 558 KB

Adjuvant chemotherapy, antiestrogen ther

Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial

✍ Charles A. Hubay; Olof H. Pearson; James S. Marshall; Robert S. Rhodes; Sara M. 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 366 KB 👁 2 views

Breast cancer adjuvant chemotherapy dosi

Breast cancer adjuvant chemotherapy dosing in obese patients : Dissemination of information from clinical trials to clinical practice

✍ Christopher G. Greenman; Christina H. Jagielski; Jennifer J. Griggs 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

## Abstract ## BACKGROUND Substantial variation in adjuvant breast cancer chemotherapy dosing in obese women suggests that there is uncertainty about optimal practices. The purpose of this study was to investigate variations in dose determinations in clinical trial protocols and publications over

Phase I trial of adjuvant chemotherapy w

Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer

✍ Stephen E. Jones; Robert G. Mennel; George N. Peters; Mary Alice Westrick; Barry 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 263 KB

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients w

Compliance with quality of life data col

Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial

✍ Patricia A. Ganz; Richard Day; Joseph Costantino 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 2 views

This paper describes compliance with the completion of a quality of life questionnaire in the Breast Cancer Prevention Trial, a large multi-centre randomized trial that is studying the efficacy of Tamoxifen in preventing breast cancer. In the first 4875 women enrolled in the control arm of the study